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Abstract 
S-acylation is the only fully reversible lipid modification of proteins however little is known about how protein S-
acyltransferases (PATs) that mediate it are regulated. DHHC5 is a plasma membrane-localised PAT with roles in 
synaptic plasticity, massive endocytosis and cancer cell growth/invasion. Here we demonstrate that stabilisation of 
DHHC5 at the plasma membrane requires binding to and palmitoylation of an accessory protein Golga7b. This 
interaction requires the palmitoylation of the C-terminus of DHHC5 which regulates the internalisation of DHHC5 
from the plasma membrane. Proteomic analysis of DHHC5/Golga7b-associated protein complexes reveals an 
enrichment in adhesion proteins, particularly components of desmosomes. We show that Desmoglein-2 and 
Plakophilin-3 are substrates of DHHC5 and that DHHC5/Golga7b are required for localisation of Desmoglein-2 to the 
plasma membrane and desmosomal patterning. Loss of DHHC5/Golga7b causes functional impairments in cell 
adhesion suggesting these proteins have a wider role in cell adhesion beyond desmosome assembly. This work 
uncovers a novel mechanism of DHHC5 regulation by Golga7b and demonstrates a role for the DHHC5/Golga7b 
complex in the regulation of cell adhesion. 
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Introduction 
S-acylation (palmitoylation) is unique amongst post-translational 
modifications as it is the only fully reversible modification that 
involves the attachment of a lipid to a protein, in this case, to the 
side chain of cysteine residues via a thioester bond. While 
palmitoylation was discovered several decades ago as a 
modification of viral proteins (Schmidt & Schlesinger, 1979), the 
progress in our understanding of palmitoylation has been slower 
than that for other modifications such as phosphorylation. For 
example, the regulation of the family of enzymes which attach 
the fatty acid onto proteins, palmitoyl acyltransferases (PATs) is 
still poorly understood. There are 23 PATs encoded in the human  
 
 
 
genome, all of which are integral membrane proteins (Korycka et 
al., 2012), with a range of cellular locations and tissue expression 
patterns (Ohno et al., 2006). They are also referred to as DHHC 
proteins as their catalytic tetrad contains the sequence Asp-His-
His-Cys which is required for palmitoylation of substrates. 
However, it has been shown that in some cases, additional 
proteins are required for PAT activity. This was first 
demonstrated in yeast, where the palmitoylation of Ras, which is 
essential for its signalling and function (Hancock et al., 1990), 
requires a complex of two proteins localised to the endoplasmic 
reticulum, Erf2 and Erf4 (Lobo et al., 2002). Subsequently, it was 
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discovered that in mammalian cells, DHHC9 requires the protein 
GCP16, also known as Golga7, to form a complex capable of 
palmitoylating Ras (Swarthout et al., 2005). The mechanism by 
which Erf4 acts on Erf2 was subsequently determined to involve 
stabilisation of the intermediate state where the acyl chain is 
transferred to the PAT before final transfer of the acyl chain to 
the substrate (Mitchell et al., 2012).  
In a large scale affinity purification-mass spectrometry 
study, Golga7b was identified as a putative interactor of DHHC5 
(Huttlin et al., 2015). Golga7b is a member of the Erf4 protein 
family which is closely related to GCP16 (Golga7) with 61% 
sequence identity. This interaction has yet to be confirmed and 
it is unknown whether Golga7b could regulate DHHC5 in a 
manner analogous to how DHHC9 is regulated by GCP16. 
Interestingly, Golga7b was also identified as a putative 
palmitoylated protein in both humans and mice (Morrison et al., 
2015; Collins et al., 2017), although confirmation of this 
palmitoylation and the identity of the cognate PAT is lacking. 
 While the majority of PATs are localised to the Golgi, 
DHHC5 is localised to the plasma membrane (Ohno et al., 2006). 
It is expressed in all tissues in mammals but it is highly enriched 
in the heart and the brain. It plays a role in the growth and 
invasion of certain types of non-small-cell lung cancer and 
DHHC5 knockdown helps to prevent the growth and invasion of 
these types of tumours (Breusegem & Seaman, 2014). DHHC5 
has few confirmed substrates, but it is known to palmitoylate the 
plasma membrane protein Flotillin-2, which is enriched in 
cholesterol rich microdomains (Li et al., 2012). In the heart, 
DHHC5 it is a key player in the phenomenon of massive 
palmitoylation-dependent endocytosis (MEND) (Hilgemann et 
al., 2013). This process occurs when oxygen is reintroduced to 
cardiac muscle cells starved of oxygen and involves the 
endocytosis of a large proportion of the plasma membrane, 
giving DHHC5 a role in the recovery of heart muscle from periods 
of anoxia (Lin et al., 2013). Additionally, an important role for 
DHHC5 in the regulation of the cardiac sodium pump through 
palmitoylation of phospholemman has been established (Howie 
et al., 2014).  
In neurons, DHHC5 is present at the post-synaptic 
density and knockout mice have defects in learning and memory 
(Li et al., 2010). DHHC5 is retained at the plasma membrane of 
the post-synaptic density through interactions with the 
scaffolding protein PSD-95 and the tyrosine kinase Fyn (Brigidi et 
al., 2015). When neurons are activated by long-term 
potentiation, phosphorylation of DHHC5 by Fyn is reduced, 
DHHC5 is lost from the complex and is endocytosed to dendritic 
ƐƉŝŶĞƐǁŚĞƌĞŝƚƉĂůŵŝƚŽǇůĂƚĞƐɷ-catenin before both proteins are 
trafficked back to the plasma membrane at the post-synaptic 
density (Brigidi et al., 2015). This type of controlled endocytic 
movement of DHHC5 has not been described for any other PAT, 
but does leave a number of open questions including the 
mechanism of endocytosis from the plasma membrane and 
whether a similar system of trafficking of DHHC5 to and from the 
plasma membrane is present in other cell types or is unique to 
neurons. 
We have identified a cluster of three palmitoylation 
sites in the C-terminus of DHHC5 (located just after its fourth 
transmembrane domain), some of which appear to be conserved 
in several other PATs (Collins et al., 2017). In brain extracts, DHHC 
exists in a predominantly palmitoylated form with several 
palmitoylated states apparent (Collins et al., 2017). The function 
of palmitoylation at these sites is unknown but we hypothesise 
that they may regulate DHHC5 localisation and/or stability. 
Indeed, recent work has established an important role for 
palmitoylation of the C-terminus of DHHC6 by DHHC16 in the 
regulation of its activity and turnover (Abrami et al., 2017). This 
region of DHHC5 is also involved in substrate recruitment; 
DHHC5 binds to and palmitoylates the sodium pump regulator 
phospholemman and this is dependent on a region of the C-
terminus of DHHC5 just after its fourth transmembrane domain 
(Howie et al., 2014). 
 A number of studies have reported that several proteins 
involved in both cell:cell and cell:matrix adhesion are 
palmitoylated and that this palmitoylation regulates localisation 
and function of these proteins (Little et al., 1998; Lievens et al., 
2016; Aramsangtienchai et al., 2017). Among adhesion protein 
complexes, desmosomes are notable as several components of 
the complex are palmitoylated (Roberts et al., 2014). 
Palmitoylation of plakophilin-3 is essential for both its inclusion 
into desmosomes and is required for the efficient assembly of 
desmosomes. One of the two desmosomal cadherins, 
desmoglein-2, is palmitoylated on a pair of cysteines (Roberts et 
al., 2016). Mutation of the palmitoylation sites of desmoglein-2 
does not prevent incorporation of desmoglein-2 into 
desmosomes but does cause a trafficking defect with a portion 
of desmoglein-2 localised to lysosomes. This shows that it is likely 
that palmitoylation plays a central role in desmosomal assembly, 
turnover and trafficking however it is unknown which PAT or 
PATs regulate this process. 
 Here we demonstrate that Golga7b interacts with 
DHHC5 and Golga7b palmitoylation regulates plasma membrane 
localisation of DHHC5. We have determined that the interaction 
between DHHC5 and Golga7b is controlled by the palmitoylation 
of the C-terminal tail of DHHC5. We also show that 
palmitoylation of golga7b prevents internalisation of DHHC5 by 
AP2-regulated clathrin mediated endocytosis. Using affinity 
purification-mass spectrometry analysis we demonstrate that 
Golga7b defines the interactome of DHHC5 and contains known 
and novel substrates as well as regulators of DHHC5. 
Investigation of selected novel substrates revealed a central role 
for DHHC5 and Golga7b in cell adhesion; DHHC5 palmitoylates 
both desmoglein-2 and plakophilin-3 and loss of DHHC5 or 
Golga7b causes defects in cell adhesion. These results uncover a 
novel palmitoylation-dependent mechanism to control the 
localisation and function of DHHC5 and reveal an important new 
role for DHHC5 in cell adhesion. 
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Results 
DHHC5 interacts with Golga7b in a palmitoylation-dependent 
manner 
Initially, we set out to confirm whether Golga7b is indeed 
palmitoylated and if Golga7b interacts with DHHC5, as both of 
these results had come from large-scale studies and had not 
been validated by targeted methods (Huttlin et al., 2015; Collins 
et al., 2017). Initial attempts to express a palmitoylation-
deficient mutant Golga7b in which cysteines in the sequence 
were mutated to alanines resulted in undetectable levels of 
expression by immunoblotting and immunofluorescence 
microscopy (data not shown). As palmitoylation regulates the 
stability of some proteins, this can lead to degradation of 
palmitoylation-deficient mutants (Ampah et al., 2018). 
Expression of mutant Golga7b with the addition of MG132 
prevented degradation of mutant Golga7b (Fig. 1a) and 
therefore, we included MG132 in all subsequent experiments 
with this construct. To measure palmitoylation we used an acyl-
biotin exchange (ABE) strategy (Drisdel et al., 2004) in which 
palmitoyl groups are selectively released by hydroxylamine at 
neutral pH, biotinylated and enriched using streptavidin resin. 
Using this approach, we found that a C-terminally FLAG-tagged 
full length wild-type (WT) Golga7b is palmitoylated when 
expressed in HeLa cells, but when the cysteines in the sequence 
were mutated to alanines, this palmitoylation was lost (Fig. 1a). 
Next, we sought to test whether DHHC5 could palmitoylate 
Golga7b using siRNA mediated knockdown of DHHC5 (Figure 
S1a) and detection of palmitoylation using ABE. When compared 
to cells that are treated with a non-targeting siRNA, there was a 
significant reduction in the palmitoylation state of Golga7b when 
DHHC5 is depleted (Fig. 1b) indicating that DHHC5 is the major 
PAT for Golga7b. 
We attempted to confirm the interaction between 
DHHC5 and Golga7b by co-immunoprecipitation using N-  
 
Figure 1: A palmitoylation-dependent interaction between DHHC5 
and Golga7b. (A) ABE blot of WT Golga7b and a palmitoylation-deficient 
mutant form of the protein with the cysteines in the sequence replaced with 
alanine residues. The presence of Golga7b signal in the +HA lane of the 
WT pulldown and not in either the ±HA lane or the +HA lane of the mutant 
shows that Golga7b is a palmitoylated protein. (B) ABE blot for Golga7b 
from HeLa cells treated with either DHHC5 siRNA or control non-targeting 
siRNA. A significant drop in the signal for Golga7b is seen in the +HA of 
the pulldown lane when DHHC5 is knocked down with siRNA. N=3, 
*=p<0.05, paired t-test. C ± Co-IP blots of WT and non-palmitoylatable 
mutant Golga7b from pulldowns of WT DHHC5 and a pair of DHHC5 
mutants (DHHS5 = catalytically inactive mutant where catalytic cysteine 
has been mutated to serine, C-terminal mutant = mutant where the 3 C-
terminal palmitoylation sites of DHHC5 have been mutated to alanine 
residues.). WT and DHHS5 could pulldown both WT and mutant Golga7b 
but the C-terminal mutant was unable to pull down either form of Golga7b 
showing that the palmitoylation of this region of DHHC5 is essential for the 
stability of this interaction. (D) Co-IP of DHHC5 with Golga7b from whole 
mouse forebrain extract. (E) Co-IP of Golga7b with DHHC5 from whole 
mouse forebrain extract. (F) ABE assay of Golga7b from mouse forebrain 
extract showing a hydroxylamine sensitive signal for Golga7b indication 
confirming that it is palmitoylated in mouse forebrain extract. 
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terminally HA-tagged DHHC5 and FLAG-tagged WT and 
palmitoylation-deficient mutant Golga7b constructs co-
expressed in HeLa cells. DHHC5 immunoprecipitated both WT 
and mutant Golga7b (Fig. 1c) which indicates that the 
palmitoylation state of Golga7b does not affect its interaction 
with DHHC5. The same is also true for a catalytically inactive form 
of DHHC5 where the catalytic cysteine is mutated to a serine 
residue (DHHS5, Figure 1c). However, when the three 
palmitoylation sites present in the C-terminal tail of DHHC5 
(Collins et al., 2017) are mutated, this mutant DHHC5 was unable 
to immunoprecipitate either the WT or mutant Golga7b (Figure 
1c) suggesting that palmitoylation of DHHC5 is directly required 
for this interaction. To confirm that the interaction of DHHC5 and 
Golga7b occurs in vivo, we performed immunoprecipitations of 
endogenous DHHC5 and Golga7b from a mouse forebrain lysate. 
This demonstrated that DHHC5 can be immunoprecipitated by 
endogenous Golga7b (Figure 1d) and that endogenous DHHC5 
can reciprocally immunoprecipitate Golga7b (Figure 1e). We 
next confirmed that endogenous Golga7b is palmitoylated in this 
context using an ABE assay (Figure 1f). These results 
demonstrate that DHHC5 and Golga7b interact in vivo and that 
DHHC5 is the major PAT for Golga7b. 
Co-expression of Golga7b and DHHC5 drives the complex to the 
plasma membrane 
We confirmed that DHHC5 is localised to the plasma membrane 
(Ohno et al., 2006) by staining for the endogenous protein in 
HeLa cells (Figure S2a). It has been reported that the over-
expression of PATs can lead to their mislocalisation (Hou et al., 
2009), which could suggest that factors that control their 
location need to be present in sufficient quantities to ensure 
proper localisation. When DHHC5 is expressed alone, staining is 
seen throughout the cell (Figure S2b) indicating that indeed 
mislocalisation occurs upon overexpression. We hypothesised 
that Golga7b might act as a regulator of DHHC5 and may be 
involved in the targeting or stabilisation of DHHC5 at the plasma 
membrane. To investigate this, we co-expressed DHHC5 with 
 
Figure 2: Regulation of DHHC5 localisation by palmitoylation of 
Golga7b and the C-terminus of DHHC5. (A) Confocal images of HeLa 
cells co-expressing WT Golga7b (1st column) and DHHC5 (2nd column), 
with a merged image (3rd column). (B) ± confocal images of HeLa cells 
co-expressing mutant Golga7b (1st column) and DHHC5 (2nd column), 
with a merged image (3rd column). (C) Confocal images of HeLa cells co-
expressing WT Golga7b (1st column) and DHHS5 (2nd column), with a 
merged image (3rd column). (D) Confocal images of HeLa cells co-
expressing mutant Golga7b (1st column) and DHHS5 (2nd column), with 
a merged image (3rd column). (E) Confocal images of HeLa cells co-
expressing WT Golga7b (1st column) and DHHC5 C-terminal mutant (2nd 
column), with a merged image (3rd column). (F) Confocal images of HeLa 
cells co-expressing mutant Golga7b (1st column) and DHHC5 C-terminal 
mutant (2nd column), with a merged image (3rd column). (G) 
Quantification of the membrane signal of DHHC5 in each of the images 
(A-F).  ****=p<0.001, n.s. = not significant, unpaired t-test. N=49, DHHC5 
+ WT Golga7b. N=53, DHHC5 + mutant Golga7b. N=40, DHHS5 + WT 
Golga7b. N=28, DHHS5 + Golga7b mutant. N=42, C-terminal mutant + 
WT Golga7b. N=31, C-terminal mutant + mutant Golga7b. 
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either WT or a palmitoylation-deficient mutant Golga7b and 
performed immunofluorescence microscopy. When DHHC5 is 
co-expressed with WT Golga7b, the majority of DHHC5 is present 
at the plasma membrane (Figure 2a). This indicates that when 
DHHC5 is overexpressed alone, there is insufficient endogenous 
Golga7b present to target or stabilise all DHHC5 protein to the 
plasma membrane. Strikingly, when DHHC5 is co-expressed with 
mutant Golga7b which cannot be palmitoylated, the majority of 
DHHC5 is lost from the plasma membrane (Figure 2b). This 
indicates that palmitoylation of Golga7b is required for the 
maintenance of DHHC5 at the plasma membrane and when this 
is prevented, DHHC5 is mislocalised. 
 Co-expression of wild-type and mutant Golga7b with 
the catalytic mutant of DHHC5 had the same effect on the 
localisation of DHHS5 as it does on the WT DHHC5 (Figures 2c 
and d), and over-expression of DHHS5 alone again shows a 
similar mislocalisation as seen with wild-type DHHC5 (Figure 
S2c). This would initially suggest that DHHC5 does not need to be 
enzymatically active for Golga7b to target DHHC5 to the plasma 
membrane. However, given that there is sufficient endogenous 
DHHC5 activity to palmitoylate overexpressed Golga7b (Figure 
1a), this is unlikely to be the case. Next, we sought to investigate 
the role of palmitoylation at the C-terminus of DHHC5 and its 
effect on DHHC5 localisation given that the palmitoylation-
deficient mutant DHHC5 is unable to interact with Golga7b. 
Unexpectedly, when we co-expressed the DHHC5 C-terminal 
palmitoylation-deficient mutant with either wild-type or mutant 
Golga7b (Figure 2e and f) it was localised to the plasma 
membrane. Furthermore, it was localised to the plasma 
membrane when over-expressed alone without Golga7b (Figure 
S2d). 
Palmitoylation of Golga7b regulates localisation of endogenous 
DHHC5 to the plasma membrane 
In order to demonstrate that Golga7b regulates the localisation 
of endogenous DHHC5, we expressed WT or mutant Golga7b in 
HeLa cells and used immunofluorescence microscopy to probe 
the localisation of endogenous DHHC5 (Figure 3). Expression of 
WT Golga7b significantly increased levels of endogenous DHHC5 
at the plasma membrane compared to endogenous DHHC5 
without Golga7b over-expression (Figure 3a, 3c and f) indicating 
that the expression level of Golga7b regulates the amount of 
plasma membrane localised DHHC5. Interestingly, over-
expression of mutant Golga7b reduces endogenous DHHC5 
localisation at the plasma membrane (Figure 3b and f), similar to 
what we observed when both DHHC5 and mutant Golga7b are 
over-expressed. This indicates that expression of a 
palmitoylation-deficient form of Golga7b prevents stabilisation 
of DHHC5 at the plasma membrane in a dominant negative 
manner. 
 In order to more definitively show that insufficient 
Golga7b leads to DHHC5 mislocalisation as was suggested by 
over-expression of DHHC5 alone (Figure S2b), we depleted 
Golga7b with siRNA in HeLa cells (Figure 3d). We observed that 
the localisation of endogenous DHHC5 was significantly reduced 
Figure 3: Regulation of plasma membrane localisation of endogenous 
DHHC5 by expression of Golga7b. (A) Confocal images of endogenous 
DHHC5 in HeLa cells over-expressing mutant Golga7b. (B) Confocal 
images of endogenous DHHC5 in HeLa cells over-expressing WT 
Golga7b. (C) Confocal images of endogenous Golga7b and DHHC5 in 
HeLa cells treated with negative control non-targeting siRNA. (D) Confocal 
images of endogenous Golga7b and DHHC5 in HeLa cell treated with 
Golga7b siRNA. (E) Confocal images of endogenous Golga7b and DHHC5 
in HeLa cell treated with Golga7b siRNA and expressing Golga7. (F) 
Quantification of plasma membrane signal of endogenous DHHC5 when 
co-expressed with WT or mutant Golga7b or without any transfected 
proteins. ****=P<0.001, t-test, endogenous + WT Golga7b n=37, 
endogenous + mutant Golga7b n=23, endogenous n=42. (G) 
Quantification of the plasma membrane signal of DHHC5 in A-C, 
****=p<0.001 t-test, control siRNA n=23, Golga7b siRNA n=23, Golga7b 
siRNA + Golga7 n=27. 
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at the plasma membrane upon Golga7b depletion, compared to 
cells treated with a non-targeting negative control siRNA where 
DHHC5 was present almost exclusively at the plasma membrane 
(Figure 3c and d). This confirms that sufficient levels of Golga7b 
are required to localise DHHC5 to the plasma membrane. To 
ensure this was an effect specific to Golga7b, we attempted to 
rescue the localisation defect of DHHC5 due to Golga7b 
depletion by expression of the closely related Golga7 (GCP16) 
(Figure 3e). Over-expression of Golga7 in Golga7b depleted cells 
failed to completely restore DHHC5 to the plasma membrane, 
suggesting that this effect is specific to Golga7b and cannot be 
significantly rescued by related proteins (Figure 3g). 
Golga7b defines DHHC5 interactomes  
As Golga7b has such a profound effect on the localisation of 
DHHC5, we used this to investigate whether the interactions of 
DHHC5 are different when it is present at the plasma membrane 
compared to when it is localised in endomembranes. To achieve 
this, a C-terminally triple FLAG-tagged DHHC5 was co-expressed 
with either WT or mutant Golga7b in HeLa cells before 
performing immunoprecipitations. Initially, we sought to prove 
that DHHC5 would immunoprecipitate proteins differentially 
when present at the plasma membrane or within the cell. We 
chose Flotillin-2 to test this as it is a known DHHC5 substrate (Li 
et al., 2012) and is present at the plasma membrane. We showed 
that DHHC5 was able to immunoprecipitate significantly more 
Flotillin-2 when it was present at the plasma membrane (co-
expressed with WT Golga7b) compared to when it was present 
at endomembranes (co-expressed with palmitoylation-deficient 
mutant Golga7b) (Figure 4a). 
In order to explore this more widely, we used an affinity 
purification-mass spectrometry (AP-MS) approach in which 
DHHC5 complexes were purified and competitively eluted by 
triple-FLAG peptide, separated by SDS PAGE, subjected to in-gel 
digestion and analysed by quantitative tandem mass 
spectrometry. We defined sets of DHHC5 interactors based on 
their quantitative enrichment in IPs versus control (non-
transfected) purifications when a) DHHC5 was localised to the 
plasma membrane (co-expressed with WT Golga7b), b) DHHC5 
was localised at endomembranes (co-expressed with 
palmitoylation-deficient mutant Golga7b), c) DHHC5 was 
localised at endomembranes (expressed alone). In order to rule 
out any effects of addition of MG132 when we co expressed 
DHHC5 with palmitoylation-deficient mutant Golga7b, we also 
generated and analysed IPs from cells which we co-expressed 
DHHC5 with wild-type Golga7b +/- MG132. Comparison of 
enriched proteins in these IPs +/- MG132 identified only one 
protein differentially enriched by the addition of MG132 
demonstrating that it did not significantly affect the set of DHHC5 
interactors. 
 Data from these experiments revealed that DHHC5 
interacts with many more proteins when localised at the plasma 
membrane by wild-type Golga7b (304 proteins, Figure 4b, Table 
S1) compared to when it is expressed with mutant Golga7b when 
it is localisaed to endomembranes (39 proteins, Table S2), with a 
small number of proteins common to both conditions (22 
proteins) (t-test with a permutation based FDR 0.05). DHHC5 
Figure 4: Proteomic analysis of context-dependent DHHC5-
associated protein complexes. (A) Co-IP western blots of Flotillin-2 from 
Hela cells co-expressing DHHC5 and either wild-type (WT) or mutant (m) 
Golga7b and quantification normalised to input, *=p<0.05, ratio paired t-
test, n=3. (B) Venn diagram comparing the overlap of numbers of proteins 
immunoprecipitated when DHHC5 is expressed alone or co-expressed 
with either WT or mutant Golga7b. (C) Scatter plot of DHHC5 interactors 
from AP-MS analysis from HeLa cells co-expressing DHHC5 and WT 
Golga7b highlighting interacting proteins involved in clathrin-mediated 
endocytosis, cell:cell adhesion and known substrates of DHHC5. (D) Co-
IP western blots of desmoglein-2 from Hela cells co-expressing DHHC5 
and either Wwild-type (WT) or mutant (m) Golga7b and quantification 
normalised to input, *=p<0.05, ratio paired t-test, n=3. (E) Co-IP western 
blots of clathrin heavy chain from Hela cells co-expressing DHHC5 and 
either wild-type (WT) or mutant (m) Golga7b and quantification normalised 
to input, *=p<0.05, ratio paired t-test, n=3. (F) Bar graph comparing the 
number of the cell:cell adhesion proteins identified in each protein 
interaction dataset. 
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does interact with a large number of proteins at the plasma 
membrane (304 proteins when DHHC5 is co-expressed with WT 
Golga7b), however, this is not uncommon for enzymes which 
may have a large number of substrates. When DHHC5 is 
expressed alone (Table S3) it interacts with some proteins also 
identified when it was co-expressed with WT Golga7b (52 
proteins). Among these are members of the AP2 complex with is 
involved in certain types of clathrin-mediated endocytosis and 
has been shown to be involved in endocytosis of DHHC5 (Brigidi 
et al., 2015). Among the proteins that are specific to the dataset 
obtained when DHHC5 is expressed on its own, perhaps the most 
interesting is a large number of proteins involved with the 
proteasome and protein degradation pathways (35 proteins). 
These proteins are not present when DHHC5 is expressed with 
either WT or mutant Golga7b, suggesting that Golga7b may offer 
DHHC5 protection from internalisation and degradation by 
stabilising DHHC5 at the plasma membrane. When DHHC5 is 
expressed alone there are many more cytoplasmic proteins 
identified as interactors compared to when it is co-expressed 
with WT Golga7b; this is likely caused by the mislocalisation of 
DHHC5 in the absence of exogenous Golga7b. 
 When we directly compared the interaction datasets 
from DHHC5 co-expressed with WT or mutant Golga7b, a 
number of proteins were differentially enriched; nine were 
enriched in the DHHC5/mutant Golga7b dataset, and 163 in the 
DHHC5/WT Golga7b dataset (t-test with a permutation based 
FDR 0.05). This clearly demonstrates the profound effect of 
Golga7b-dependent localisation of DHHC5 has on its 
interactome. To validate this, we chose two proteins that were 
differently enriched between the WT and mutant Golga7b 
conditions that were not known DHHC5 interactors or 
substrates. Both desmoglein-2, a desmosomal cadherin, and the 
clathrin heavy chain, an important endocytosis protein, 
interacted with DHHC5 significantly more when DHHC5 was at 
the plasma membrane (co-expressed with WT Golga7b) 
compared to when it was at endomembranes (co-expressed with 
mutant Golga7b) (Figures 5d and e), showing that both of these 
proteins are bona fide DHHC5 interactors and that our AP-MS 
results are reliable. 
 Among the set of proteins that were significantly 
enriched when DHHC5 was expressed with WT Golga7b 
compared to mutant Golga7b was a number of proteins 
associated with clathrin-mediated endocytosis, including three 
major members of the AP2 complex (Figure 4c), plus the clathrin 
light and heavy chain. This indicates that the endocytosis of 
DHHC5 may be mediated by this complex, as DHHC5 is known to 
be actively trafficked away from the plasma membrane in 
neurons (Brigidi et al., 2015) and has a number of endocytic 
sequences in its C-terminal tail. When looking at the proteins 
that interact with DHHC5 when it is co-expressed with WT 
Golga7b, nine of the top ten over-represented gene ontology 
terms are involved with cell:cell or cell:matrix adhesion (Figure 
4f). While it is known that a number of proteins involved in 
adhesion are palmitoylated (Roberts et al., 2014; Lievens et al., 
2016; Aramsangtienchai et al., 2017), the PATs responsible are 
mostly unknown. Given the large number of proteins 
immunoprecipitated by DHHC5, particularly in the desmosomal 
cell adhesion complex, we hypothesised that DHHC5 is the PAT 
responsible for the palmitoylation of these proteins and could be 
a key player in regulating cellular adhesion. In particular, it was 
noted that the desmosomal cadherin Desmoglein-2, which is a 
known palmitoylated protein (Roberts et al., 2014), and the Tight 
junction protein ZO-1 which opens up the possibility that 
palmitoylation by DHHC5 is an important regulatory process in 
these two different processes in cell adhesion.  
Palmitoylation of golga7b prevents internalisation of DHHC5 
As several of the clathrin mediated endocytosis complex 
members were found as interactors of DHHC5 in our AP-MS 
study (Figure 4c), we decided to further investigate the 
mechanism of DHHC5 internalisation and endocytosis. Given that 
palmitoylation of Golga7b is required to localise DHHC5 at the 
plasma membrane, we sought to better understand the 
mechanism of internalisation of DHHC5. We first investigated 
whether it was possible to rescue mislocalisation of DHHC5 when 
co-expressed with mutant Golga7b by inhibiting the clathrin-
mediated endocytosis. When HeLa cells expressing WT DHHC5 
and mutant Golga7b are treated with 25µM dynasore, the 
majority of DHHC5 is stabilised at the plasma membrane after a 
relatively short time (within 30 minutes) (Figure 5a and b). This 
shows that DHHC5 is rapidly trafficked to and from the plasma 
membrane in a number of cell types outside of what has been 
found previously in neurons (Brigidi et al., 2015). It also suggests 
a role for Golga7b in stabilising DHHC5 at the plasma membrane 
by preventing endocytosis.  
As dynasore may have some off-target effects (Park et 
al., 2013), we validated these observations using siRNA 
knockdown of the AP2µ subunit, which was found as an 
interactor of DHHC5 in the AP-MS experiments. When AP2µ is 
depleted, it leads to a significant drop in the endocytosis of the 
transferrin receptor and had a noticeable impact on the number 
of clathrin coated pits formed in cells (Motley et al., 2003). When 
we depleted AP2µ in HeLa cells co-expressing WT DHHC5 and 
mutant Golga7b, DHHC5 was restored to the plasma membrane, 
while in cells treated with a control non-targeting siRNA DHHC5 
remained within the cell (Figure 5c and d). This confirms that 
DHHC5 requires AP2µ for endocytosis from the plasma 
membrane (Brigidi et al., 2015) and that palmitoylation of 
Golga7b prevents endocytosis of DHHC5. Importantly, this 
demonstrates conclusively that palmitoylation deficient Golga7b 
does not prevent DHHC5 association with the plasma membrane 
and that palmitoylated Golga7b acts by stabilising DHHC5 at the 
plasma membrane.  
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DHHC5/Golga7b regulates desmosome trafficking & assembly 
As a number of proteins involved in cell adhesion were found as 
DHHC5 interactors in our AP-MS study (Figure 4c), we wanted to 
investigate whether any of these proteins were DHHC5 
substrates and if DHHC5 is involved in cell adhesion. Among 
these is the important desmosomal cadherin desmoglein-2 
(DSG2, Figure 4d). DSG2 is a known palmitoylated protein 
(Roberts et al., 2016), where its palmitoylation regulates the 
localisation and trafficking of the protein to the plasma 
membrane. Because of this, we decided to investigate whether 
DHHC5 is the PAT responsible for DSG2 palmitoylation, so we 
performed an ABE assay on DHHC5 depleted HeLa cells and 
control siRNA treated cells (Figure 6a). We found that upon 
DHHC5 depletion, DSG2 palmitoylation is almost completely 
abolished, showing that DHHC5 is the PAT responsible for the 
majority, if not all, of DSG2 palmitoylation. It also suggests that 
our AP-MS approach allows the discovery of new substrates of 
PATs, however, this may not be viable in all cases as it is known 
that some PATs only interact weakly with some of their 
substrates (Lemonidis et al., 2014). 
 Given that palmitoylation of DSG2 regulates its 
localisation to the plasma membrane and trafficking it to 
desmosomes, we investigated the effect of DHHC5 knockdown 
on the localisation and trafficking of DSG2 using 
immunofluorescence microscopy of A431 cells with DHHC5 
depletion and calcium switch assays. In culture, desmosomes are 
calcium dependent, so when cells are cultured in a medium that 
is free from calcium desmosomes are rapidly internalised and 
trafficked back to the plasma membrane when calcium is re-
introduced. In A431 cells treated with a non-targeting negative 
control siRNA, DSG2 returned to the plasma membrane gradually 
over the three-hour time course when calcium was added to the 
media (Figure 6b, Figure S3). However, when DHHC5 was 
depleted, DSG2 signal remained within the cell, with no 
significant change in the level of DSG2 at the plasma membrane 
during the three-hour time course (Figure 6c, Figure S4). This 
shows that depletion of DHHC5 significantly inhibits the 
trafficking of DSG2 to the plasma membrane. 
 In order to establish if Golga7b plays a functional role in 
desmosome assembly through its regulation of DHHC5 
localisation, we determined the effect of Golga7b depletion on 
the trafficking of DSG2. As with DHHC5, A431 cells were treated 
with Golga7b siRNA and a calcium switch performed. Again, after 
three hours of calcium being returned to the media, DSG2 had 
not returned to the plasma membrane at the same level as cells 
treated with a non-targeting siRNA (Figure 6d). This links DHHC5 
location to the correct trafficking of DSG2 and implicates 
Golga7b in the regulation of DHHC5 substrates. 
 The DSG2 localisation phenotype is similar to that seen 
when palmitoylation of the desmosomal protein Plakophilin-3 
(PKP3) is prevented (Roberts et al., 2014). PKP3 was not found as 
an interactor of DHHC5, but the localisation of DSG2 after DHHC5 
depletion is similar to palmitoylation-deficient PKP3 mutants 
(Roberts et al., 2014). We treated HeLa cells with either DHHC5 
siRNA or non-targeting control siRNA, performed ABE assays to 
measure palmitoylation levels of PKP3 and found that there was 
Figure 5: AP2-mediated endocytosis of DHHC5 requires 
palmitoylated Golga7b. (A) 30 minute DMSO treatment of HeLa cells co-
expressing WT DHHC5 and mutant Golga7b. (B) 30 minute Dynasore 
treatment (25µM) of HeLa cells co-expressing WT DHHC5 and mutant 
Golga7b. (C) Non-targeting control siRNA treatment (10nM) of HeLa cells 
expressing mutant Golga7b. (D) AP2µ siRNA treatment (10nM) of HeLa 
cells that were subsequently transfected with mutant Golga7b. (E) 
Quantification of plasma membrane signal of DHHC5 in A and B. 
****=p<0.001, unpaired t-test. N=37, +dynasore. N=28, +DMSO.  (F) 
Quantification of plasma membrane signal of DHHC5 in D and E. 
****=p<0.001, unpaired t-test. 
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a significant and almost total loss of palmitoylation of PKP3 
compared to a non-targeting siRNA (Figure 6f). This shows that 
PKP3 is a DHHC5 substrate and makes it likely that the phenotype 
seen with DSG2 localisation and trafficking is caused by a 
combination of the loss of palmitoylation of both DSG2 and PKP3. 
 
DHHC5/Golga7b regulates cell adhesion 
To investigate whether DHHC5 plays a more general role in cell 
adhesion, or if the localisation and palmitoylation defects 
observed in desmosomes are sufficient to cause a loss of cell 
adhesion, we used a modified form of a cell scatter assay. When 
cells are exposed to a growth factor they internalise their cell:cell 
and cell:matrix adhesion proteins which cause cells to scatter 
away from the colonies they naturally form and mimics epithelial 
to mesenchymal transition. All cell adhesion proteins are 
targeted in this assay, but a deficiency in one of more aspects of 
the adhesion machinery will lead to a change in scattering. The 
speed and distance of this scattering are dependent on cell 
adhesion with reduced adhesion leading to enhanced scattering. 
When A431 cells were subject to DHHC5 depletion before 
treatment with low levels of EGF (5ng/ml), cells scattered 
noticeably (Figure 7b and c), whereas control non-targeting 
siRNA treated cells remained in colonies when treated with the 
same concentration of EGF (Figure 7a and c). This shows that 
depletion of DHHC5 leads to a reduction of adhesion of cells to 
one another and implicates DHHC5 in a wider role in cell:cell 
adhesion, as in order to scatter, cells must lose all cell:cell 
junctions including desmosomes and tight junctions (Chen, 
2005).  
To test if depletion of Golga7b mirrors the effects seen 
with DHHC5 depletion in the calcium switch assay, we performed 
cell scatter assays on Golga7b depleted A431 cells (Figure 7 d-f). 
We observed enhanced scattering of cells upon Golga7b 
depletion compared to control cells exposed to a non-targeting 
siRNA. This shows Golga7b has a functional role in cell adhesion 
which is likely to be caused by its regulation of DHHC5 
localisation. Given that we have shown that DHHC5 interacts not 
only with DSG2 but also with Tight junction protein ZO-1 (Table 
S2), it is possible that the wider effects that DHHC5 depletion has 
on cell adhesion could be caused by disruption of both 
desmosomes and tight junctions. 
 To further demonstrate a functional role of DHHC5 and 
Golga7b in cell adhesion, we performed trans-epithelial electrical 
resistance assays. This involves the growth of cells on a semi-
permeable membrane support and measurement of the 
electrical resistance across this membrane (Chen et al., 2015); 
Figure 6: Desmogelin-2 palmitoylation by DHHC5/Golga7b regulates 
its plasma membrane localisation and incorporation into 
desmosomes. (A) ABE western blot for desmoglein-2 (DSG2) from HeLa 
cells treated with 10nM non-targeting siRNA (nt siRNA) or DHHC5 siRNA. 
Loss of the band in the +HA pulldown in the DHHC5 siRNA condition 
shows that DSG2 palmitoylation is dependent on DHHC5. (B) Confocal 
images of DHHC5 and DSG2 in nt siRNA treated A431 cells three hours 
after calcium was reintroduced to the media in calcium switch 
experiments. (C) Confocal images of DHHC5 and DSG2 in DHHC5 siRNA 
treated A431 cells three hours after calcium was reintroduced to the media 
in calcium switch experiments. (D) Confocal images of DHHC5, DSG2 and 
Golga7b in Golga7b siRNA treated A431 cells three hours after calcium 
was reintroduced to the media in calcium switch experiments. (E) 
Quantification of the percentage of total signal DSG2 seen at the plasma 
membrane and within the cell (internal) after 3 hours in calcium switch 
experiments in either nt siRNA or DHHC5 siRNA conditions. ****=p<0.001, 
unpaired t-test. N=24, DHHC5 siRNA. N=25, control siRNA. N=26, 
Golga7b siRNA. (F) ABE western blot for plakophilin-3 (pkp3) from HeLa 
cells treated with 10nM non-targeting siRNA (nt siRNA) or DHHC5 siRNA. 
Loss of the band in the +HA pulldown in the DHHC5 siRNA condition 
shows a DHHC5-dependent loss of pkp3 palmitoylation. 
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the stronger the cell adhesion, the higher the resistance 
measurement will be. When we performed this assay on 
confluent A431 cells that were treated with either DHHC5 or 
negative control non-targeting siRNA, we observed a significant 
reduction in electrical resistance in cell cultures treated with 
DHHC5 or Golga7b siRNA (Figure 7g). This shows that the 
adhesion between the cells is reduced in these conditions 
highlighting that the DHHC5/Golga7b complex is an important 
regulator of the cell adhesion machinery. 
Discussion 
The regulation of subcellular localisation of many PATs is poorly 
understood, and DHHC5 is unique among them as it is the only 
known PAT to exhibit dynamic changes in localisation in response 
to external stimuli (Brigidi et al., 2015). While it has been shown 
in neurons that the localisation of DHHC5 is regulated by 
phosphorylation, we have shown that the localisation of DHHC5 
is also regulated by the interaction and palmitoylation of an 
accessory protein, Golga7b. It is notable that the over-expression 
of palmitoylation-deficient mutant Golga7b causes 
mislocalisation of endogenous DHHC5 which suggests that 
Golga7b has a dominant negative effect on DHHC5. Over-
expression of the WT Golga7b increased localisation of 
endogenous DHHC5 at the plasma membrane, which further 
strengthens the argument that the level of Golga7b within the 
cell is an important determinant of DHHC5 localisation. The 
catalytically dead DHHC5 (DHHS5) mutant like wild-type DHHC5 
localises to the plasma membrane when co-expressed with 
Golga7b. However, wild-type Golga7b is readily palmitoylated 
when expressed in HeLa cells (Figure 1a), which suggests that 
endogenous DHHC5 is sufficient to palmitoylate Golga7b to a 
level required for correct localisation of DHHS5. 
 Palmitoylation sites in the C-terminus of DHHC5 are 
required for its interaction with Golga7b and stabilisation at the 
plasma membrane. Mutation of these palmitoylation sites 
appears to prevent internalisation of DHHC5 from the plasma 
membrane. Sorting signals in the C-terminal tails of PATs are 
important factors in controlling their localisation and are able to 
switch the localisation of a PAT from the Golgi to the ER (Gorleku 
et al., 2011). Our results suggest that palmitoylation of DHHC5 is 
not required for correct trafficking of DHHC5 to the plasma 
membrane nor for the interaction between DHHC5 and the 
endocytic machinery as the endocytic interaction motifs are 
unaffected by these mutations (Brigidi et al., 2015). The data 
presented here suggest that when palmitoylated DHHC5 is not 
bound to Golga7b, it is endocytosed. Preventing palmitoylation 
of the GluR1 subunit of the AMPA receptor inhibits its 
endocytosis (Hayashi et al., 2005), which is similar to what we 
propose for DHHC5. Interestingly, the three palmitoylation sites 
on the C-terminal tail of DHHC5 map to an amphipathic alpha 
helix in the corresponding crystal structure of DHHC20 (Rana et 
al., 2018) and this palmitoylation could potentially pin this helix 
to the plasma membrane thereby altering the conformation of 
the C-terminal tail. As the majority of DHHC5 is palmitoylated on 
two or more sites in vivo (Collins et al., 2017), it suggests that 
palmitoylation could play a major role in the regulation of cell 
surface expression of DHHC5.  
The observation that DHHC5 requires an interaction 
with Golga7b for stabilisation at the plasma membrane appears 
to be in conflict with the finding that C-terminal DHHC5 mutant, 
which does not interact with Golga7b, is stabilised at the plasma 
membrane. The DHHC5 C-terminal mutant, while being unable 
Figure 7: Cell adhesion is regulated by DHHC5/Golga7b. (A) 10x 
brightfield images of A431 cells treated with non-targeting siRNA at time 
0 (left) and after 48 hours (right) of 5 ng/ml EGF treatment. (B) 10x 
brightfield images of A431 cells treated with DHHC5 siRNA at time 0 (left) 
and after 48 hours (right) of 5ng/ml EGF treatment. (C) Quantification of 
cell scattering of A431 cells, showing a significant difference in cell scatter 
after 48 hours of DHHC5 knockdown. N=3, n=31. **= p<0.005, unpaired 
t-test. (D) 10x brightfield images of A431 cells treated with non-targeting 
siRNA at time 0 (left) and after 48 hours (right) of 5ng/ml EGF treatment. 
(E)  10x brightfield images of A431 cells treated with Golga7b siRNA at 
time 0 (left) and after 48 hours (right) of 5ng/ml EGF treatment. (F) 
Quantification of cell scattering of A431 cells, showing a significant 
difference in cell scatter after 48 hours of DHHC5 knockdown. N=3, n=31. 
**= p<0.005, unpaired t-test. (G) Plot showing the resistance of A431 cells 
from a trans-epithelial electrical resistance assay treated with either 
DHHC5 siRNA, Golga7b siRNA or non-targeting siRNA. N=12, 
****=p<0.001, unpaired t-test, ***=p<0.01, unpaired t-test 
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to interact with Golga7b, is unable to be internalised because it 
is not palmitoylated on its C-terminus. This raises the possibility 
that the interaction with Golga7b functions to protect C-
terminally palmitoylated DHHC5 from endocytosis and suggests 
that palmitoylation of the C-terminal tail of DHHC5 is an 
endocytic trigger for the protein. 
Activity-dependent trafficking of DHHC5 has been 
described to occur in neurons after long-term potentiation 
(Brigidi et al., 2015). Here, we have confirmed that DHHC5 is 
endocytosed from the plasma membrane by the AP2-regulated 
clathrin mediated endocytosis pathway in HeLa cells. 
Interestingly, the results presented here suggest that DHHC5 is 
trafficked as part of its normal lifecycle and does not require 
stimulation of cells in any way, as DHHC5 is restored to the 
plasma membrane within 30 minutes of dynasore treatment. 
This could be a general feature of DHHC5 in all cell types or it 
could have different cycling dynamics in various specialised cell 
types. Importantly, inhibition of endocytosis corrects the 
localisation defect when DHHC5 is co-expressed with mutant 
Golga7b. This demonstrates that the palmitoylation deficient 
Golga7b does not prevent insertion of DHHC5 into the plasma 
membrane. Instead, Golga7b acts to stabilise DHHC5 at the 
plasma membrane by preventing its internalisation.  
 Our unbiased AP-MS experiments uncovered a new role 
for DHHC5 in cell adhesion. Palmitoylation regulates several 
proteins involved in cell:cell and cell:matrix adhesion (Little et al., 
1998; Roberts et al., 2014; Lievens et al., 2016; Roberts et al., 
2016; Aramsangtienchai et al., 2017) and for many of them, 
palmitoylation regulates their localisation. Among cell adhesion 
complexes, desmosomes are notable for the number of proteins 
in the complex that are palmitoylated, with at least 6 members 
of the complex palmitoylated in A431 cells (Roberts et al., 2014), 
and in this work, we have shown that DHHC5 is the PAT 
responsible for the palmitoylation of the key complex members 
desmoglein-2 and plakophilin-3. We have also demonstrated 
that knockdown of DHHC5 affects the trafficking and localisation 
of DSG2, which had been demonstrated previously to be 
dependent on DSG2 palmitoylation, albeit with a noticeably 
milder phenotype than we observed (Roberts et al., 2016). It is 
also notable that the knockdown of Golga7b also caused defects 
in DSG2 localisation and trafficking demonstrating a functional 
role for Golga7b in cell adhesion. Plasma membrane localisation 
of DHHC5 is required for the correct trafficking and localisation 
of DSG2. This implies that plasma membrane localisation of 
DHHC5 is needed for efficient DSG2 palmitoylation, trafficking 
and incorporation into desmosomes. However, this appears to 
contradict the previous work which suggested that 
palmitoylation of DSG2 occurs at the Golgi which facilitates 
trafficking to the plasma membrane (Roberts et al., 2016).  The 
reasons for this apparent contradiction are unclear, but the same 
study showed that palmitoylation-deficient DSG2 is still able to 
reach the plasma membrane, indicating that palmitoylation of 
DSG2 is not strictly required for trafficking to the plasma 
membrane and that once DSG2 reaches the plasma membrane it 
is palmitoylated by DHHC5 which facilitates its incorporation and 
therefore stabilisation in desmosomal complexes. However, 
DHHC5 appears to cycle between the plasma membrane and 
endomembranes, making is possible that DSG2 is palmitoylated 
by DHHC5 at non plasma membrane sites, similar to what has 
been demonstrated for ɷ-catenin at dendritic spines (Brigidi et 
al., 2015).  
Furthermore, we have determined that plakophilin-3 is 
also a DHHC5 substrate and as it has been shown previously that 
palmitoylation of plakophilin-3 regulates the localisation of DSG2 
as well as a number of other desmosomal components (Roberts 
et al., 2014), this would indicate that DHHC5 regulates the 
localisation and assembly of desmosomes more generally. The 
finding that plakophilin-3 is a DHHC5 substrate also helps to 
explain why the localisation and trafficking phenotype of DSG2 
upon DHHC5 knockdown is more severe than when DSG2 
palmitoylation alone is prevented. Loss of PKP3 palmitoylation 
has a profound effect on the localisation of DSG2 (Roberts et al., 
2016). These findings reveal a completely novel role for DHHC5 
in the regulation of desmosome function. 
We established a broader role for DHHC5 in cell 
adhesion by observing increased scattering of DHHC5 depleted 
cells due to a reduction in cell adhesion. To our knowledge, this 
is the first report of a specific PAT that regulates the 
palmitoylation of essential adhesion proteins and that its 
depletion leads to defects in cell adhesion. The link between 
DHHC5 and adhesion is not without precedent, however, as a 
number of known DHHC5 substrates have roles in cell adhesion. 
Flotillin-2 regulates the stability of desmoglein-3 at the plasma 
membrane and depletion of Flot2 leads to reduced desmosomal 
adhesion (Vollner et al., 2016). As DHHC5 is the PAT responsible 
for Flot2 palmitoylation (Li et al., 2012), it is possible that DHHC5 
could have a role in desmosomal adhesion through this pathway 
in addition to palmitoylation of PKP3 and DSG2 as demonstrated 
in ƚŚŝƐǁŽƌŬ ?ŶŽƚŚĞƌ,, ?ƐƵďƐƚƌĂƚĞɷ-catenin (Brigidi et al., 
2014) competes with p120ctn to interact with the adhesion 
protein E-ĐĂĚŚĞƌŝŶ ? ɷ-catenin binding to E-cadherin reduces 
p120ctn at cell junctions and inhibits adhesion and E-cadherin 
binds to desmogleins 2 and 3 to promote desmosome formation 
(Shafraz et al., 2018). This suggests that DHHC5 could influence 
the assembly, stability and location of desmosomes through a 
number of mechanisms, and this work shows that it has a direct 
regulatory role for at least two members of the demosomal 
protein complex. 
The regulation of cell adhesion by DHHC5 has some 
potentially interesting implications for DHHC5 in disease. 
Disruption of desmosomes in the heart is known to lead to the 
serious heart condition arrhythmogenic right ventricular 
cardiomyopathy (ARVC) (Kant et al., 2015).  To the best of our 
knowledge, palmitoylation of desmosomal proteins has not been 
implicated in ARVC to date, but given that DHHC5 has been 
shown to be enriched in the heart (Ohno et al., 2006), it is 
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possible that palmitoylation of desmosomal proteins by DHHC5 
in the heart could play a role in this condition. It also opens up 
the possibility of DHHC5 being used as a marker for potential 
cancer metastasis, as the results presented here suggest that a 
lower level of DHHC5 in a cell would lead to an increased chance 
of metastasis due to reduced cell adhesion.  
 In conclusion, the results presented in this work 
establish a new mechanism of DHHC5 localisation through the 
action of Golga7b and implicate DHHC5 and Golga7b as 
important members of cellular adhesion machinery. Going 
forward, the exact molecular mechanism of how Golga7b 
influences DHHC5 localisation and how their interaction is 
mediated will be important questions to address to fully 
understand this novel regulatory mechanism. It will also be 
important to investigate the triggers that control the endocytosis 
of DHHC5 and how palmitoylation and phosphorylation of 
DHHC5 work in concert to control its presence at the plasma 
membrane.  
 
Materials and methods 
Cell culture 
All cells were grown in normal DMEM (Gibco) supplemented with 1% 
penicillin/sptreptomycin (Gibco), except for during Calcium switch 
experiments, when A431 cells were grown in calcium free DMEM 
(Gibco). All transfection was carried out using polyethylinimine (PEI, 
25kDa linear, Alfa Aesar) using a ratio of 1:3 of DNA:PEI with cells 
allowed to grow for 24 hours after transfection before harvesting or 
fixing unless otherwise stated. For siRNA treatments, siRNA was mixed 
with mission siRNA transfection siRNA transfection reagent (Sigma 
Aldrich) and incubated for 30 minutes at room temperature before the 
mixture was added to cells. SiRNA used: DHHC5, Golga7b, AP2µ, 
universal non-targeting control (All Dharmacon, SMARTPool) 
Constructs 
N-terminally HA-tagged DHHC5 construct was a kind gift from Dr 
Andrew Peden. All other contructs were ordered from Genscript with 
either human DHHC5 (GeneID 25921) or human Golga7b (GeneID 
401647) as templates. All ORF clones were under the CMV promoter in 
the pcDNA3.1+ vector which had either a FLAG or HA tag following the 
protein coding region before the stop codon. SiRNA was obtained from 
Dharmafect. 
Antibodies 
Anti-DHHC5 (Atlas Antibodies), for ICC 1:250, for immunoblotting 
1:1000. Anti-Golga7b (Bioss Antibodies), for ICC 1:100, for 
immunoblotting 1:1000. Anti-FLAG (Sigma Aldrich), for ICC 1:500, for 
immunoblotting 1:1000. Anti-HA (Sigma Aldrich), for ICC 1:200. Anti-
AP2µ (Genetex), for ICC 1:150, for immunoblotting 1:1000. Anti-DSG2 
(Santa Cruz Biotech), for ICC 1:200, for immunoblotting 1:250. Anti-PKP3 
(Santa Cruz Biotech), for immunoblotting 1:200. Anti-Flotillin-2 (Cell 
Signalling Technology), for immunoblotting 1:1000. Anti-Actin (Cell 
Signalling Technology), for immunoblotting 1:2500. Anti-Rabbit HRP 
(Thermo Fisher Scientific), for immunoblotting 1:2500. Anti-Mouse HRP 
(Cell Signalling Technology), for immunoblotting 1:2500. Anti-Mouse 
Alexa Fluor 488 (Invitrogen), for ICC 1:2500. Anti-Rabbit Alexa Fluor 594 
(Invitrogen), for ICC 1:2500. Anti-Chicken Alexa Fluor 647 (Invitrogen), 
for ICC 1:2500. 
Acyl-Biotin Exchange 
Cell pellets were collected and resuspended in lysis buffer (2.5% sds, 
50mM Tris pH 7.2, 50mM NaCl, 1mM EDTA) and then homogenised 
using an electric homogeniser for 15 seconds. Lysates were heated at 
70°C for 15 minutes before being centrifuged at 16,000xg for 10 minutes 
and the supernatants retained. After cooling, maleimide (Sigma Aldrich) 
was added to 100mM final concentration and incubated for 3 hours at 
40°C with shaking. Samples were then acetone precipitated by the 
addition of 4x volume of -20°C acetone and resuspended twice in lysis 
buffer with 5 washes with ice cold acetone after each precipitation to 
remove any excess maleimide. Lysates were split into + and  ? 
hydroxylamine (HA) treatment conditions. The +HA samples had 2M 
hydroxylamine/50mM Tris pH 7.4 added to a final hydroxylamine 
concentration of 1M, while the  ?HA samples had an equal volume of 
50mM Tris pH 7.4 added. HA was made fresh immediately before use 
and prepared by dissolving hydroxylamine in distilled water before the 
pH was adjusted up to 7.4 with NaOH. EZ link Biotin-HPDP (Thermo 
Fisher) dissolved in DMSO, mixed with N,N-dimethylformamide and 
then added to samples at a final concentration of 0.5mM. Samples were 
then incubated for 1 hour at 37°C with shaking. Proteins were 
precipitated with acetone and then washed 4 times with ice cold 
acetone to remove any excess biotin. Protein was resuspended in IP 
buffer (1% triton x-100, 50mM tris pH 7.2, 150mM NaCl, 1mM EDTA, 
protease inhibitor cocktail 1:200 (Sigma)) and incubated with 30µl of 
streptavidin-sepharose resin (Thermo Fisher), which was prewashed 
twice with IP buffer, for 1 hour at room temperature with end-over-end 
rotation. The resin was washed 4 times in the IPbuffer before elution of 
bound proteins by the addition of 20mM TCEP for 20 minutes at 37°C 
with shaking. Eluted proteins were collected by centrifugation at 800xg 
for 5 minutes and the supernatants were retained. Samples were stored 
at -20°C until further use. 
Immunoprecipitation 
Cell pellets were collected and immediately resuspended in lysis buffer 
(1% triton x-100, 50mM tris pH 7.2, 150mM NaCl, 1mM EDTA, protease 
inhibitor cocktail 1:200 (Sigma)). Samples were then rotated end-over-
end at 4°c for 30 minutes before spinning at 16,000xg for 5 mins. The 
supernatants were retained. 100µl of anti-FLAG M2 resin (Sigma Aldrich 
 ? A2220) was washed in lysis buffer without protease inhibitors 3 times, 
added to the samples and then left overnight with end-over-end 
rotation at 4°c. Samples were then spun at 800xg for 2 minutes to collect 
the resin before being washed 5 times for 5 minutes each at room 
temperature with end-over-end rotation with lysis buffer without 
protease inhibitors. Immunoprecipitated proteins were eluted by 3 
times resin bed volume of 2mg/ml triple FLAG peptide (Sigma Aldrich) 
dissolved in lysis buffer without protease inhibitors for 30 mins at room 
temperature with end over end rotation. The samples were then 
centrifuged at 800xg for 5 minutes and the supernatants retained. 
Eluted proteins were stored at -20°C until further use. For 
immunoprecipitations of endogenous proteins from mouse forebrain, a 
whole mouse forebrain was added to a lysis buffer (1% triton x-100, 1% 
sodium deoxycholate, 50mM tris pH 7.2, 150mM NaCl, 1mM EDTA, 
protease inhibitor cocktail 1:200 (Sigma)) and homogenised 10 times 
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with a dounce homogeniser on ice. Samples were spun at 16,000xg and 
the supernatant retained as above. Samples were pre-cleared with 
protein G sepharose before centrifugation and retention of the 
supernatant. Samples were then incubated with either anti-DHHC5 or 
anti-Golga7b antibodies and protein G sepharose overnight at 4°C. The 
resin was then washed 5 times with lysis buffer before elution of bound 
proteins by heating the resin for 20 minutes at 70°C. 
Immunocytochemistry 
Cells were seeded onto glass coverslips in a 12 well plate and were 
grown for 24 hours. The media was changed and cells were transfected 
with a 3:1 ratio of PEI:cDNA for 24 hours as described previously. Media 
was removed, coverslips were washed briefly with 1-2 ml of PBS and 
cells were fixed with 4% PFA for 10 minutes at room temperature. Cover 
slips were washed again with PBS before permeabilisation with 0.3% 
triton x-100-PBS (vol/vol) for 15 minutes at room temperature with 
gentle agitation. After washing with PBS, coverslips were blocked with 
0.2% fish skin gelatin (Sigma Aldrich)/0.01% triton x-100 (vol/vol) in PBS 
(blocking solution) for an hour at room temperature with agitation. 
Primary antibody was incubated at the concentrations mentioned 
previously diluted in blocking solution for 1 hour at room temperature. 
Coverslips were washed three times for 5 minutes with 1ml of PBS with 
gentle agitation before incubation with secondary antibodies diluted in 
blocking solution for 2 hours at room temperature, protected from light 
by wrapping plates in tin foil with gentle agitation. Coverslips were then 
washed with 1ml of PBS 3 times for 5 minutes with gentle agitation 
before mounting on glass slides with DAPI fluoromount-G mounting 
media (Southern Biotech) before being kept in dark at 4°C before 
confocal imaging. 
Calcium switch assays 
A431 cells were seeded on glass coverslips in a 12 well plate with either 
normal DMEM or low Calcium DMEM and placed back into the incubator 
for 18 hours. Control or targeted siRNA was then added as described 
previously and cells were placed back into the incubator for 72 hours. 
ĂůA?ǁĂƐƚŚĞŶĂĚĚĞĚƚŽƚŚĞůŽǁĐĂůĐŝƵŵŵĞĚŝĂƚŽĂĨŝŶĂůĐŽŶĐĞŶƚƌĂƚŝŽŶ
of 2mM for 30 minutes, 1 or 3 hours. Control cells were left in low 
calcium media. Cells were then fixed with 4% PFA and prepared as 
described previously in the immunocytochemistry section. 
Confocal Microscopy 
All confocal microscopy was performed on a Nikon A1 confocal 
microscope using the following laser wavelengths: 405nm (blue), 488nm 
(green), 561nm (red) and 640nm (far-red). Images were acquired using 
a 60x objective lens and the NIS elements program (Nikon instruments) 
in an ND2 format. For all samples, no primary and no secondary controls 
were used to threshold the exposure at each individual laser 
wavelength. All images were analysed using the FIJI (Schindelin et al., 
2012) and imageJ (Schneider et al., 2012) software packages. To assess 
plasma membrane or internal protein signal, the colour channels were 
split to isolate the channel of interest. The free draw tool was used to 
draw around a single cell and the mean intensity, raw integrated density 
and integrated density were measured. The shape was then moved just 
within the plasma membrane of the cell and the same measurements 
recorded. The ratio of the two means was then used to calculate the 
level of protein signal at the plasma membrane (higher ratio indicates 
more signal at the plasma membrane). 
Immunoblotting 
Samples were run on 10% tris-glycine acrylamide gels unless otherwise 
stated and proteins were transferred to 0.2µm polyvinylidene difluoride 
membranes (Thermo Fisher) for 90 minutes at 30V Membranes were 
blocked for 1 hour at room temperature on a roller in pbs 0.1%-tween-
20 (vol/vol, pbs-t) 5% skim milk powder (weight/vol), before overnight 
incubation with primary antibody diluted in pbs-t 1% skim milk powder 
(weight/vol) at 4°C on a roller. Membranes were then washed 5 times 
with 10 ml pbs-t for 5 minutes each on a roller at room temperature, 
before incubation with secondary antibody diluted in pbs-t 1% milk for 
1 hour at room temperature. Membranes were washed again 5 times 
with 10ml pbs-t for 5 minutes before a final wash with 10ml pbs. Clarity 
ECL solution (Bio-Rad) was added in a 1:1 ratio of peroxide 
solution:luminol/enhancer solution with a final volume of 10ml for 5 
minutes at room temperature on a roller before another wash with pbs 
on a roller at room temperature. Blots were imaged by exposure on CL-
X posure x-ray film (Thermo Fisher) prior to development to visualise 
protein bands. 
Mass spectrometry 
In-gel digestion was performed as reported previously (Bayes et al., 
2017). Extracted peptides were re-suspended in 0.5% formic acid and 
analysed by nanoflow LC-MS/MS using an Orbitrap Elite (Thermo Fisher) 
hybrid mass spectrometer equipped with a nanospray source, coupled 
to an Ultimate RSLCnano LC System (Dionex). The system was controlled 
by Xcalibur 2.1 (Thermo Fisher) and DCMSLink 2.08 (Dionex). Peptides 
were desalted on-line using a micro-Precolumn cartridge (C18 Pepmap 
100, LC Packings) and then separated using a 130 minute gradient from 
3%-40% buffer B (0.5% formic acid in 80% acetonitrile)  on an EASY-
^ƉƌĂǇ ĐŽůƵŵŶ ?  ? ?രĐŵരA?ര ? ?രA?ŵ / ? WĞƉDĂƉ  ? ? ?  ?രA?ŵ ƉĂƌƚŝĐůĞƐ ?  ? ? ?ര
pore size (Thermo). The LTQ-Orbitrap Elite was operated with a cycle of 
one MS (in the Orbitrap) acquired at a resolution of 60,000 at m/z 400, 
with the top 20 most abundant multiply-ĐŚĂƌŐĞĚ ? ?രA?രĂŶĚŚŝŐŚĞƌ ?ŝŽŶƐŝŶ
a given chromatographic window subjected to MS/MS fragmentation in 
the linear ion trap. An FTMS target value of 1e6 and an ion trap MSn 
target value of 1e4 was used and with the lock mass (445.120025) 
ĞŶĂďůĞĚ ? DĂǆŝŵƵŵ &dD^ ƐĐĂŶ ĂĐĐƵŵƵůĂƚŝŽŶ ƚŝŵĞ ŽĨ  ? ? ?രŵƐ ĂŶĚ
ŵĂǆŝŵƵŵŝŽŶƚƌĂƉD^ŶƐĐĂŶĂĐĐƵŵƵůĂƚŝŽŶƚŝŵĞŽĨ ? ? ?രŵƐǁĞƌĞƵƐĞĚ ?
ǇŶĂŵŝĐĞǆĐůƵƐŝŽŶǁĂƐĞŶĂďůĞĚǁŝƚŚĂƌĞƉĞĂƚĚƵƌĂƚŝŽŶŽĨ ? ?രƐǁŝƚŚĂŶ
exclusion list of 500 and ĂŶ ĞǆĐůƵƐŝŽŶ ĚƵƌĂƚŝŽŶ ŽĨ  ? ?രƐ ? dŚĞ ŵĂƐƐ
spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE [1] partner repository with 
the dataset identifier PXD011553 
Mass spectrometry data analysis 
All raw mass spectrometry data was analysed with MaxQuant version 
1.5.6 (Cox & Mann, 2008). Data were searched against a human UniProt 
sequence databases (downloaded June 2015) using following search 
parameters: digestion set to Trypsin/P, methionine oxidation and N-
terminal protein acetylation as variable modifications, cysteine 
carbamidomethylation as a fixed modification, match between runs was 
enabled with a match time window of 0.7 minutes and a 20 minute 
alignment time window, label free quantification was enabled with a 
minimum ratio count of 2, minimum number of neighbours of 3 and an 
average number of neighbours of 6. PSM and protein match thresholds 
were set at 0.1ppm. A protein FDR of 0.01 and a peptide FDR of 0.01 was 
used for identification level cut offs. For immunoprecipitation data, 
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protein groups file generated by MaxQuant were loaded into the 
Perseus platform (Tyanova et al., 2016) with the LFQ intensity from each 
individual run as main columns. The matrix was filtered to remove all 
proteins that were potential contaminants, only identified by site and 
reverse sequences. The LFQ intensities were then transformed by 
log2(x) and individual LFQ columns were grouped by experiment (e.g. all 
control experiments grouped, all DHHC5 pulldowns grouped etc.). Rows 
without valid values in 3 out of 4 runs in at least one of the groups were 
removed and all remaining missing values were replaced from the 
normal distribution with each column imputed individually. Following 
this, a two-ƚĂŝůĞĚ^ƚƵĚĞŶƚ ?Ɛd-test with S0 set to 3 and a permutation 
based FDR of 0.05 was performed and all non-significant proteins were 
removed and the matrix was exported in a .txt format for further 
analysis. For further filtering of results, files analysed using the online 
Contaminant Repository for Affinity Purification Mass Spectrometry 
Data program (Mellacheruvu et al., 2013) with additional controls 
(CC130, CC135, CC136, CC137). Proteins with an SP score above 0.95 
were considered bona fide interactors. Gene ontology analysis was 
performed using the WebGestalt platform (Zhang et al., 2005) with the 
following parameters: species set to homo sapiens, reference gene set 
ǁĂƐ “ŐĞŶŽŵĞƉƌŽƚĞŝŶĐŽĚŝŶŐ ? ?&ZƐĞƚƚŽ ? ? ? ?ǁŝƚŚĞŶũĂŶŝ,ŽĐŚďĞƌŐ
multiple test adjustment. 
Cell Scatter Assay 
10,000 A431 cells were seeded in single wells of 6 well plates 24 hours 
after treatment with either DHHC5 or non-targeting siRNA. Cells were 
grown for 24 hours before media was removed and replaced with serum 
free DMEM and cells were incubated for 8 hours. Cells were imaged at 
10x magnification on a Nikon Widefield microscope system, positions of 
fields of view recorded, EGF was added to a final concentration of 
5ng/ml and cells were incubated for 48 hours. Cells were then imaged 
again at the same positions as previously. To quantify scattering, the grid 
tool of ImageJ was used, with the number of grid squares occupied by 
cells compared at 0 and 48 hours. 
Trans-epithelial electrical resistance 
125,000 A431 cells were seeded in transwell inserts in 24 well plates 
which had a 0.4µm pore size. Cells were allowed to grow for 12 hours 
until confluency before treatment with siRNA, which was performed for 
24 hours. The resistance in each well was measured 3 times with an 
epithelial voltohmmeter. The measurements for each well were 
averaged and a blank value of a transwell insert without cells was 
subtracted from each measurement before statistical analysis. 
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